Anzeige
Mehr »
Login
Mittwoch, 22.01.2025 Börsentäglich über 12.000 News von 682 internationalen Medien
STRONG BUY! Kurs eskaliert - A Star is Born!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
650 Leser
Artikel bewerten:
(2)

Chubb Secures Insurance Partnership Deal with Revolut

Finanznachrichten News

LONDON, Jan. 19, 2021 /PRNewswire/ -- Chubb has today announced the launch of a new insurance partnership with Revolut, a financial technology company delivering digital banking services.

The partnership programme provides a wide range of coverage for Revolut's customers, including purchase protection, refund protection and ticket cancellation, where a Revolut account is used.

The policy also offers coverage where a customer has a confirmed diagnosis of COVID-19 and is therefore unable to use event tickets purchased using their Revolut account.

Chubb was selected as the carrier due to its multinational capabilities and global footprint, together with its leading accident and health propositions and strong partnerships expertise. The programme will be rolled out across 22 countries.

"We are delighted with our new digital partnership with Revolut. We strive to build long-term, successful relationships with our insurance partners that deliver value for the partner and their clients. For us Revolut is a good example of digital innovation that aligns with our own ambitions," said Florian Eisele, Director of Accident and Health, Continental Europe.

"Our new partnership with Revolut marks a significant step for Chubb as we continue to drive relationships in the digital space. We are looking forward to working with the Revolut team to deliver valuable insurance solutions to their customers," said Goulven Thépot, Regional Head of Underwriting, Accident and Health, Continental Europe.

"We're always looking to provide the best value possible to our customers and help them get more from their money. We're constantly improving our paid plans and are delighted to partner with Chubb to add purchase protection, refund protection and ticket cancellation for our customers," said Felix Jamestin, Head of Premium Product at Revolut.

About Chubb

Chubb is the world's largest publicly traded property and casualty insurance company. With operations in 54 countries and territories, Chubb provides commercial and personal property and casualty insurance, personal accident and supplemental health insurance, reinsurance and life insurance to a diverse group of clients. As an underwriting company, we assess, assume and manage risk with insight and discipline. We service and pay our claims fairly and promptly. The company is also defined by its extensive product and service offerings, broad distribution capabilities, exceptional financial strength and local operations globally. Parent company Chubb Limited is listed on the New York Stock Exchange (NYSE: CB) and is a component of the S&P 500 index. Chubb supports executive offices in Zurich, New York, London, Paris and other locations, and employs approximately 33,000 people worldwide. Additional information can be found at: www.chubb.com.

About Revolut

Revolut is building the world's first truly global financial superapp. In 2015, Revolut launched in the UK offering money transfer and exchange. Today, over 13 million customers around the world use dozens of Revolut's innovative products to make more than 100 million transactions a month. Across our personal and business accounts, we help customers improve their financial health, give them more control, and connect people seamlessly across the world. www.revolut.com

Logo - https://mma.prnewswire.com/media/324916/Chubb_Logo.jpg

© 2021 PR Newswire
Gewinner im Megamarkt
Biotechnologie ist eine der bedeutendsten Zukunftstechnologien unserer Zeit. Zahlreiche Biotechnologie- und Pharmakonzerne haben sich unter anderem dem Kampf gegen Tumorerkrankungen verschrieben. Der weltweite Markt für Krebsmedikamente verzeichnet ein stetiges Wachstum. Für das Jahr 2025 wird ein Umsatz von etwa 190,3 Milliarden Euro prognostiziert, mit einer erwarteten jährlichen Wachstumsrate von 6,42% bis 2029, was zu einem geschätzten Marktvolumen von 244,1 Milliarden Euro führen würde.

Wir haben 3 aussichtsreiche Biotechnologieaktien mit Schwerpunkt Erforschung und Entwicklung von Wirkstoffen gegen Tumorerkrankungen ausfindig gemacht, die in den kommenden Monaten und Jahren erhebliches Aufwärtspotenzial versprechen und Vervielfachungspotenzial besitzen.

Fordern Sie jetzt unseren neuen kostenlosen Spezialreport an und erfahren Sie, welche 3 Biotech-Aktien durchstarten und zu Ihrem Börsenerfolg in 2025 beitragen könnten!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.